J
Jian Zhang
Researcher at Harbin Medical University
Publications - 9
Citations - 370
Jian Zhang is an academic researcher from Harbin Medical University. The author has contributed to research in topics: Gene & Internal medicine. The author has an hindex of 5, co-authored 6 publications receiving 225 citations.
Papers
More filters
Journal ArticleDOI
Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells
TL;DR: The results showed that BRD4 expression levels were higher in cancer tissues than in normal tissues and were related to poor prognosis in cancer patients, and the anticancer effect of (+)-JQ1 was enhanced by ferroptosis inducers.
Journal ArticleDOI
The emergence of noncoding RNAs as Heracles in autophagy.
TL;DR: The current knowledge regarding noncoding RNA dysregulation in autophagy is summarized and the molecular regulatory mechanisms underlying nonc coding RNA involvement in autophile regulatory networks are investigated to provide new insights to specifically targetNoncoding RNAs in Autophagy-associated therapeutic strategies.
Journal ArticleDOI
Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer
Shouping Xu,Peiyuan Wang,Jian Zhang,Hao Wu,Shiyao Sui,Jinfeng Zhang,Qin Wang,Kun Qiao,Weiwei Yang,Hongbiao Xu,Da Pang,Da Pang +11 more
TL;DR: Proper regulation of EGOT may be a novel synergistic strategy for enhancing paclitaxel sensitivity in cancer therapy and broaden comprehensive understanding of the biology function of Ai-lncRNAs.
Journal ArticleDOI
The transcriptional landscape of lncRNAs reveals the oncogenic function of LINC00511 in ER-negative breast cancer.
TL;DR: The role of lncRNAs in regulating the network of cell cycle control in ER-negative breast cancer is revealed and the exploitation of LINC00511 as an anticancer therapy in the future is suggested.
Journal ArticleDOI
Hypoxia-Induced TPM2 Methylation is Associated with Chemoresistance and Poor Prognosis in Breast Cancer.
Jinfeng Zhang,Jian Zhang,Shouping Xu,Xianyu Zhang,Peiyuan Wang,Hao Wu,Bingshu Xia,Guangwen Zhang,Bo Lei,Lin Wan,Dekai Zhang,Da Pang +11 more
TL;DR: TPM2 is associated with poor survival and Chemoresistance to paclitaxel in breast cancer, and TPM2 may represent a promising therapeutic gene target for breast cancer patients with chemoresistance.